Understanding MASLD — and How to Support a Healthier Liver

What MASLD Actually Is

Metabolic dysfunction-associated steatotic liver disease is the leading cause of liver disease, affecting up to 30% of the global population at varying degrees of severity. The nomenclature was changed from non-alcoholic fatty liver disease (NAFLD) in 2023 following international consensus acknowledging the importance of reducing stigma and using inclusive rather than exclusive descriptors.

The name change matters beyond semantics. NAFLD defined the condition by what it was not — non-alcoholic. MASLD defines it by what it is — a metabolic condition driven by insulin resistance, excess dietary energy, and the liver's inability to process the resulting fat load. That framing more accurately describes the biology and directs attention toward the modifiable factors that drive it.

The condition develops when the liver is asked to process more energy, sugar, and fat than it can efficiently handle. Fat begins to accumulate within liver cells — a state called hepatic steatosis. In many people this remains stable. In approximately 20 to 30% of cases it progresses to MASH — metabolic dysfunction-associated steatohepatitis — where fat accumulation is accompanied by inflammation and liver cell damage. From MASH, a proportion of patients progress to fibrosis, cirrhosis, and ultimately liver failure or hepatocellular carcinoma.

In a large cohort study, 7 to 10% of patients diagnosed with MASH progress to cirrhosis over a period of 10 years. The trajectory is slow enough to be intercepted — but only if the condition is identified and addressed before significant scarring occurs.

Why MASLD Matters More Than Most People Realise

MASLD is estimated to affect up to one in five people in the UK. Mortality rates in England alone rose by 44% between 2019 and 2023, with the highest rates seen in the North of England.

With the rise of obesity, hepatic steatosis now affects around a third of the UK population to varying degrees, frequently coexisting with other cardiometabolic conditions such as type 2 diabetes and ischaemic heart disease.

The liver-heart connection is one of the most important and least appreciated aspects of MASLD. The condition does not operate in isolation — it drives and is driven by the same metabolic dysfunction that produces cardiovascular disease, type 2 diabetes, and chronic kidney disease. A 2025 study found that high blood pressure and low HDL cholesterol were stronger predictors of death in MASLD than blood glucose — reinforcing the cardiovascular significance of what is often framed purely as a liver condition.

Among 687 people with MASLD surveyed by the British Liver Trust, 68% were overweight or obese and 35% had type 2 diabetes. Over a third said their diagnosis came at a late stage, when it was too late for effective treatment.

Why the Name Changed — and What MetALD Means

The 2023 consensus renaming from NAFLD to MASLD also introduced a related diagnosis: MetALD — describing people who have both metabolic dysfunction and moderate alcohol intake (defined as 140 to 350g per week for women, 210 to 420g per week for men). This sits between MASLD and alcohol-related liver disease, acknowledging that for many people, both metabolic and alcohol factors are present simultaneously.

The practical importance: someone with MetALD faces compounding liver insults. Addressing both the metabolic component and the alcohol component is necessary — addressing only one leaves the other as an ongoing driver of progression.

What Causes MASLD

The condition rarely has a single cause. It develops from a convergence of metabolic and lifestyle factors:

Insulin resistance — when cells stop responding efficiently to insulin, the pancreas produces more of it, and excess glucose is converted to fat and deposited in the liver. Insulin resistance is present in most people with MASLD and is the central driver of disease.

Dietary overload from ultra-processed foods and sugar — high intake of fructose, refined carbohydrates, and saturated fat from ultra-processed foods drives de novo lipogenesis — the process by which the liver converts excess sugar into fat. Fructose, in particular, is processed almost exclusively by the liver and is particularly strongly associated with hepatic fat accumulation.

Physical inactivity and low muscle mass — skeletal muscle is a primary site of glucose disposal. Low muscle mass and sedentary behaviour reduce the body's capacity to clear glucose, amplifying the insulin resistance that drives MASLD.

Sleep disruption and chronic stress — elevated cortisol from chronic stress and sleep deprivation increases glucose production, promotes visceral fat accumulation, and worsens insulin sensitivity. The sleep-liver connection is well established: shift workers and people with sleep apnoea show significantly higher rates of MASLD.

Gut microbiome dysbiosis — disrupted gut bacteria accelerate MASLD progression through increased intestinal permeability, allowing bacterial products to enter the portal circulation and drive hepatic inflammation. The gut-liver axis is now recognised as a significant pathway in MASLD pathogenesis, and gut-targeted interventions — dietary fibre, fermented foods — are increasingly incorporated into management approaches.

Genetic factors — variants in the PNPLA3 and TM6SF2 genes significantly increase susceptibility to MASLD and its progression. These genetic factors partly explain why some people develop MASLD without obvious metabolic risk factors, and why disease severity varies so considerably between individuals with similar lifestyle profiles.

Symptoms and How It Is Diagnosed

Most people with MASLD have no obvious symptoms until the condition has reached an advanced stage. This is both the defining clinical challenge and the reason awareness matters.

Possible early indicators include: persistent fatigue or brain fog without an obvious cause; mild discomfort or a sense of fullness under the right rib cage; raised liver enzymes (ALT, AST) on a routine blood test; high triglycerides, low HDL cholesterol, or borderline fasting glucose.

Most patients with MASLD will be diagnosed in the community through investigation of deranged liver function tests or incidentally on abdominal ultrasound. A FibroScan — a non-invasive ultrasound-based measurement of liver stiffness — is increasingly used in primary care to assess fibrosis stage without the need for biopsy. New AI-enhanced MRI imaging models are improving early detection accuracy in research settings, with clinical translation expected over the next several years.

If you have a combination of overweight or obesity, type 2 diabetes, high triglycerides, high blood pressure, or a family history of liver disease, proactive screening through your GP is worth pursuing — not waiting for symptoms that may not appear until significant damage has occurred.

What Actually Works: The Evidence on Treatment

Weight Loss: The Primary Therapeutic Target

Clinically meaningful and sustained weight loss of 10% or more of total body weight is the primary therapeutic target for patients with MASLD. This level of weight loss is associated with significant reduction in hepatic fat, regression of inflammation in MASH, and in some cases reversal of early fibrosis.

Even modest weight loss — 5 to 7% — produces meaningful reductions in liver fat and improves metabolic markers. Ten percent or more is associated with histological improvement in MASH, including regression of fibrosis in a significant proportion of patients. This is the goal that dietary and lifestyle programmes need to be designed around.

The Mediterranean Diet

The Mediterranean dietary pattern — high in vegetables, olive oil, oily fish, legumes, nuts, and whole grains, low in ultra-processed foods and saturated fat from red meat — is the most consistently evidence-supported dietary approach for MASLD. It reduces hepatic fat through multiple mechanisms: improving insulin sensitivity, reducing de novo lipogenesis, providing anti-inflammatory fatty acids, and supporting the gut microbiome.

Specific dietary changes with the strongest evidence:

• Eliminate fructose-containing drinks — sugary drinks and fruit juices are the single highest-impact dietary change for most people with MASLD. The fructose load from a daily sugary drink produces measurable increases in hepatic fat within weeks.
• Reduce refined carbohydrates — white bread, white rice, pastries, and ultra-processed foods with high glycaemic load drive insulin resistance and hepatic fat accumulation. Replacing with whole grain alternatives improves metabolic markers consistently.
• Increase dietary fibre — particularly from diverse plant sources, to support the gut microbiome and reduce intestinal permeability, addressing the gut-liver axis component of MASLD progression.
• Increase oily fish and olive oil — omega-3 fatty acids from oily fish reduce hepatic triglycerides and have direct anti-inflammatory effects in the liver. Olive oil's oleocanthal has documented anti-inflammatory properties.
• Reduce alcohol — even within the MetALD range, alcohol compounds liver insults in people with metabolic dysfunction. Reduction or elimination, particularly during active treatment, is clinically recommended.

Physical Activity

Regular exercise improves insulin sensitivity, reduces hepatic fat, and supports the weight loss required for meaningful MASLD improvement — even when weight loss itself is modest. Both aerobic exercise and resistance training have evidence for reducing liver fat independently of weight change.

The practical recommendation: 150 to 300 minutes per week of moderate-intensity aerobic exercise, alongside at least two sessions per week of resistance training. For people with limited fitness, starting with daily brisk walking and gradually increasing duration and intensity is more sustainable than high-intensity programmes that produce early dropout.

GLP-1 Medications

New obesity pharmacotherapies hold significant promise in MASLD, given their ability to produce dramatic weight loss of 10 to 25% and improve cardiometabolic health. GLP-1 receptor agonists including semaglutide and the dual agonist tirzepatide have shown particular promise in MASLD given their mechanism of action.

Multiple trials have shown that semaglutide at 2.4mg weekly produces significant reductions in hepatic fat and MASH activity scores alongside its weight loss effects. Tirzepatide's greater weight loss magnitude makes it particularly relevant for MASLD patients who need substantial weight reduction to achieve histological improvement. For a deeper dive, see GLP-1 Drugs and Liver Health and our Weight Loss Injections UK 2026 comparison.

These medications are not indicated for MASLD specifically — they are prescribed for obesity or type 2 diabetes. But for people who meet the eligibility criteria for these medications and have MASLD, the liver benefits are a meaningful additional argument for their use within the appropriate clinical framework.

The First Approved MASLD Drug

The first medication specifically approved for MASLD — resmetirom — was approved by the US FDA in March 2024 for the treatment of adults with non-cirrhotic MASH with moderate-to-advanced fibrosis. Resmetirom is a thyroid hormone receptor-beta agonist that specifically targets hepatic fat metabolism. It is not yet licensed in the UK, where NICE approval is pending. For most people in the UK, lifestyle change remains the only approved treatment.

Monitoring Progress

Regular monitoring matters both for tracking improvement and for maintaining motivation during what is typically a months-long process.

Blood tests including ALT, AST, and a fasting lipid panel every three to six months provide evidence of liver enzyme normalisation and metabolic improvement. A repeat FibroScan after 12 months of consistent lifestyle change gives a direct assessment of liver stiffness progression or regression. Weight, waist circumference, and fasting glucose provide additional markers that correlate with liver health.

Many people see improvements in energy, digestion, and cognitive clarity within weeks of meaningful dietary changes — before any imaging or blood test confirms the liver benefit. These early functional improvements are genuine and reflect the rapid response of the metabolic system to reduced carbohydrate and fructose load.

Frequently Asked Questions

What is the difference between MASLD and NAFLD?

MASLD and NAFLD describe the same condition — fatty liver disease unrelated to alcohol in people with metabolic risk factors. The name changed in 2023 following international consensus that the old term was stigmatising and defined the condition by what it was not. MASLD focuses on the metabolic drivers — insulin resistance, obesity, type 2 diabetes — and better reflects the biology and treatment approach.

Can MASLD be reversed?

Yes — particularly in its early stages. Early MASLD is one of the most reversible metabolic conditions. Weight loss of 5 to 7% produces meaningful reductions in liver fat; 10% or more is associated with improvement in liver inflammation and in some cases reversal of early fibrosis. The earlier the condition is identified and addressed, the better the prognosis. Advanced fibrosis and cirrhosis are significantly harder to reverse.

What are the symptoms of MASLD?

Most people with MASLD have no symptoms — which is why it is so commonly diagnosed late. Possible early indicators include persistent fatigue or brain fog, mild discomfort under the right rib cage, and raised liver enzymes on a blood test. High triglycerides, low HDL cholesterol, or borderline fasting glucose alongside being overweight are significant risk indicators that warrant proactive screening.

How much weight do I need to lose to improve MASLD?

A loss of 5 to 7% of total body weight produces measurable improvements in liver fat and metabolic markers. Ten percent or more is associated with histological improvement in MASH — regression of inflammation and in some cases fibrosis. This is the target that most clinical guidelines use as a benchmark for meaningful therapeutic benefit.

Is fatty liver disease the same as MASLD?

Broadly yes — MASLD is currently the most widely used clinical term for what was previously called non-alcoholic fatty liver disease or fatty liver disease. It specifically refers to fat accumulation in the liver associated with metabolic risk factors, as distinct from alcohol-related fatty liver disease. The two conditions share some mechanisms but have different management implications, particularly regarding alcohol.

Can you have MASLD if you are not overweight?

Yes — MASLD can occur in people with a normal BMI, particularly those with insulin resistance, high visceral fat relative to overall body weight, or specific genetic variants including PNPLA3 and TM6SF2. This is sometimes called lean MASLD and carries similar progression risks to obesity-associated MASLD. Genetic susceptibility partly explains why some normal-weight people develop the condition while some obese people do not.

The Bottom Line

MASLD is the most common chronic liver disease in the UK, affecting up to one in three adults, and its prevalence is rising in direct parallel with obesity and ultra-processed food consumption. It is largely silent in its early stages, frequently diagnosed late, and inadequately supported in clinical practice — with more than half of people with MASLD receiving no lifestyle guidance following diagnosis.

The good news is that early MASLD responds meaningfully to lifestyle change — particularly weight loss, dietary improvement, and regular physical activity. The evidence is clear and the interventions are accessible. What is needed is awareness, early identification, and consistent support.

For a structured approach to supporting liver health through dietary and lifestyle change, the Liver Reset from the Reset Series™ provides a practical protocol. The Sugar Reset specifically addresses the fructose and refined carbohydrate load that is most directly linked to hepatic fat accumulation.

Related reading: GLP-1 Drugs and Liver Health: What the Research Shows · Weight Loss Injections UK 2026: Mounjaro vs Wegovy vs Ozempic Compared · Do Ultra-Processed Foods Increase Heart Disease Risk?

Popular Articles